JP6475713B2 - 標的修飾ｉｌ−１ファミリーメンバー - Google Patents

標的修飾ｉｌ−１ファミリーメンバー Download PDF

Info

Publication number
JP6475713B2
JP6475713B2 JP2016526518A JP2016526518A JP6475713B2 JP 6475713 B2 JP6475713 B2 JP 6475713B2 JP 2016526518 A JP2016526518 A JP 2016526518A JP 2016526518 A JP2016526518 A JP 2016526518A JP 6475713 B2 JP6475713 B2 JP 6475713B2
Authority
JP
Japan
Prior art keywords
composition
cells
targeting moiety
her2
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016526518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527221A5 (enExample
JP2016527221A (ja
Inventor
タヴェルニエール，ジャン
ゲルロ，サラ
ペエルマン，フランク
ウゼ，ジルス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montpellier
Original Assignee
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montpellier filed Critical Universite de Montpellier
Publication of JP2016527221A publication Critical patent/JP2016527221A/ja
Publication of JP2016527221A5 publication Critical patent/JP2016527221A5/ja
Application granted granted Critical
Publication of JP6475713B2 publication Critical patent/JP6475713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016526518A 2013-07-19 2014-07-04 標的修飾ｉｌ−１ファミリーメンバー Active JP6475713B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306047.5 2013-07-19
EP13306047 2013-07-19
PCT/EP2014/064283 WO2015007542A1 (en) 2013-07-19 2014-07-04 Targeted modified il-1 family members

Publications (3)

Publication Number Publication Date
JP2016527221A JP2016527221A (ja) 2016-09-08
JP2016527221A5 JP2016527221A5 (enExample) 2017-08-10
JP6475713B2 true JP6475713B2 (ja) 2019-02-27

Family

ID=48874235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526518A Active JP6475713B2 (ja) 2013-07-19 2014-07-04 標的修飾ｉｌ−１ファミリーメンバー

Country Status (14)

Country Link
US (5) US9932409B2 (enExample)
EP (1) EP3022226B1 (enExample)
JP (1) JP6475713B2 (enExample)
KR (1) KR102275090B1 (enExample)
CN (1) CN105612180B (enExample)
AU (1) AU2014292377B2 (enExample)
BR (1) BR112016001128A2 (enExample)
CA (1) CA2918518C (enExample)
DK (1) DK3022226T3 (enExample)
ES (1) ES2714504T3 (enExample)
IL (1) IL243466B (enExample)
MX (1) MX370348B (enExample)
SG (1) SG11201600167SA (enExample)
WO (1) WO2015007542A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3368559A4 (en) 2015-10-30 2020-01-15 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3368077A4 (en) 2015-10-30 2019-10-16 Aleta Biotherapeutics Inc. COMPOSITIONS AND METHODS FOR TUMOR TRANSDUCTION
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
EP3411407B1 (en) 2016-02-05 2024-04-03 Orionis Biosciences BV Bispecific signaling agents and uses thereof
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
EP3529264B1 (en) 2016-10-24 2022-03-09 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2018160993A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
KR102659140B1 (ko) 2017-08-09 2024-04-19 오리오니스 바이오사이언시스 인코포레이티드 Clec9a 결합제 및 그의 용도
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
CA3069930A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Cd8 binding agents
EP3733716A4 (en) * 2017-12-26 2021-11-24 Nanjing GenScript Biotech Co., Ltd. DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
EP3833391A4 (en) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
KR20220012227A (ko) 2019-03-28 2022-02-03 오리오니스 바이오사이언시즈 인코포레이티드 Clec9a-기반 키메라 단백질 복합체
CA3133643A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
US20230293652A1 (en) * 2020-07-07 2023-09-21 Orionis Biosciences, Inc. Immunostimulatory adjuvants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE103932T1 (de) 1989-08-22 1994-04-15 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
WO2001029870A1 (en) * 1999-10-21 2001-04-26 Sarnoff Corporation Bi-potential electrode space-saving cathode ray tube
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
US7947265B2 (en) 2006-08-02 2011-05-24 Mcgill University Fusion proteins and methods for modulation of immune response
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
JP2010531666A (ja) 2007-06-26 2010-09-30 ユニバーシティ オブ マイアミ 抗体−エンドスタチン融合タンパク質及びそのバリアント
EP2853267B1 (en) 2007-09-21 2016-12-07 The Regents of the University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
WO2010036918A2 (en) * 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
AU2009326075B2 (en) 2008-12-08 2014-06-05 Complix Nv Single-chain antiparallel coiled coil proteins
CA2769619C (en) * 2009-08-17 2019-04-30 Roche Glycart Ag Targeted immunoconjugates
WO2011029870A1 (en) * 2009-09-10 2011-03-17 Cytos Biotechnology Ag Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
US9534056B2 (en) 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
EA034989B1 (ru) 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
WO2013107791A1 (en) 2012-01-20 2013-07-25 Vib Vzw Targeted mutant alpha-helical bundle cytokines
WO2013134138A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules

Also Published As

Publication number Publication date
ES2714504T3 (es) 2019-05-28
EP3022226A1 (en) 2016-05-25
DK3022226T3 (en) 2019-03-25
CA2918518A1 (en) 2015-01-22
US9932409B2 (en) 2018-04-03
KR102275090B1 (ko) 2021-07-09
US20200255545A1 (en) 2020-08-13
AU2014292377A1 (en) 2016-02-04
KR20160108293A (ko) 2016-09-19
CN105612180B (zh) 2019-11-12
BR112016001128A2 (pt) 2018-01-23
JP2016527221A (ja) 2016-09-08
MX370348B (es) 2019-12-10
US20190202934A1 (en) 2019-07-04
US20180186894A1 (en) 2018-07-05
WO2015007542A1 (en) 2015-01-22
AU2014292377B2 (en) 2019-08-01
SG11201600167SA (en) 2016-02-26
EP3022226B1 (en) 2018-12-05
MX2016000723A (es) 2016-12-20
US20230235086A1 (en) 2023-07-27
IL243466A0 (en) 2016-03-31
IL243466B (en) 2019-11-28
CN105612180A (zh) 2016-05-25
CA2918518C (en) 2022-08-16
US20160152730A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
JP6475713B2 (ja) 標的修飾ｉｌ−１ファミリーメンバー
US8388964B2 (en) Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
US20210017247A1 (en) Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
CN110461871A (zh) 白蛋白结合结构域融合蛋白
CN108948177A (zh) 融合分子与il-15变异体
CN107922470A (zh) 对lag‑3和pd‑1特异性的新型融合多肽
US20250136664A1 (en) Switch receptors using il-9 signaling domains
JP2023510871A (ja) Ｉｌ２ムテイン
JP2021527047A (ja) 消化管系へのペイロード送達のための、ｂｔｎｌ３／８を標的とする構築物
US20240156980A1 (en) Protease cleavable prodrugs
HK1225048A1 (en) Targeted modified il-1 family members
HK1225048B (en) Targeted modified il-1 family members
WO2025007057A2 (en) Lymphocyte trafficking receptor and ligand
TW202502807A (zh) 融合il10多肽
WO2024005204A1 (ja) 融合タンパク質
CN117242094A (zh) 蛋白酶可切割的前药

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190201

R150 Certificate of patent or registration of utility model

Ref document number: 6475713

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250